AB Science S.A. (EPA:AB)
France · Delayed Price · Currency is EUR 1.182
-0.036 (-2.96%)
Apr 2, 2026, 5:35 PM CET
AB Science Employees
AB Science had 36 employees as of June 30, 2025. The number of employees decreased by 3 or -7.69% since the number was reported on December 31, 2024.
Employees
36
Change
-3
Growth
-7.69%
Revenue / Employee
€28,528
Profits / Employee
€237,194
Market Cap
86.22M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 36 | -3 | -7.69% | 36 | 0 |
| Dec 31, 2024 | 39 | -18 | -31.58% | 28 | 11 |
| Dec 31, 2023 | 57 | -46 | -44.66% | 51 | 6 |
| Dec 31, 2022 | 103 | 5 | 5.10% | 103 | 0 |
| Dec 31, 2021 | 98 | 6 | 6.52% | 98 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 155,975 |
| Sanofi | 74,846 |
| Sartorius Stedim Biotech | 10,265 |
| Ipsen | 5,535 |
| Guerbet | 2,905 |
| Eurofins-Cerep | 207 |
| Innate Pharma | 174 |
| Crossject Société Anonyme | 103 |
AB Science News
- 5 weeks ago - AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS - GlobeNewsWire
- 7 weeks ago - Stonegate Capital Partners Initiates Coverage on AB Science S.A. (AB) - Newsfile Corp
- 7 weeks ago - AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors - GlobeNewsWire
- 2 months ago - AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041 - GlobeNewsWire
- 3 months ago - AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia - GlobeNewsWire
- 3 months ago - AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040 - GlobeNewsWire
- 3 months ago - AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share - GlobeNewsWire
- 3 months ago - AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers - GlobeNewsWire